BIOXYTRAN, INC
For the period ended Mar 31, 2025. Filed May 15, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 15, 2025
BIXTStored price and day change unavailable
Contents
Item 1. Consolidated Balance Sheets as of March 31, 2025, and December 31, 2024, (Unaudited)
CONSOLIDATED BALANCE SHEETS
**MARCH 31, 2025 AND DECEMBER 31,**2024
| March 31, 2025 unaudited | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash | $4,348 | $5,154 |
| Total current assets | 4,348 | 5,154 |
| Intangibles, net | 131,704 | 133,540 |
| Total assets | $136,052 | $138,694 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $555,792 | $271,308 |
| Accounts payable affiliates | 7,683 | 154,236 |
| Un-issued shares liability | 11,920 | 91,729 |
| Un-issued shares liability affiliates | 16,680 | 132,639 |
| Loan from related Party | 407,610 | 241,078 |
| Other short-term loans | 48,000 | 48,000 |
| Convertible notes payable, net of premium and discount | 805,000 | 805,000 |
| Derivative liability | 991,404 | 186,652 |
| Total current liabilities | 2,844,089 | 1,930,642 |
| Total liabilities | 2,844,089 | 1,930,642 |
| Commitments and contingencies | — | — |
| Stockholders’ deficit: | ||
| Preferred stock, $0.001 par value; 50,000,000 shares authorized, and 43,398,388 and 43,158,248 issued and outstanding as at March 31, 2025, and as at December 31, 2024, respectively | 43,398 | 43,158 |
| Common stock, $0.001 par value; 400,000,000 shares authorized; 88,881,859 and 86,782,908 issued and outstanding as at March 31, 2025, and December 31, 2024, respectively | 88,882 | 86,783 |
| Additional paid-in capital | 17,434,486 | 16,999,280 |
| Accumulated deficit | (20,274,803) | (18,921,169) |
| Total stockholders’ deficit | (2,708,037) | (1,791,948) |
| Total liabilities and stockholders’ equity | $136,052 | $138,694 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.